IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

ConferenceDarovasertibIDE849Positive

AI Analysis

Summary

IDEAYA Biosciences announced three abstract presentations for its Darovasertib and IDE849 clinical programs at the 2026 European Society of Medical Oncology (ESMO) meeting in October 2026.

Importance:4/10

Sentiment:

0.30

conference presentationESMO 2026oncologyprecision medicineclinical programs

Related Companies

$IDYA

Read the original article

Published by PR Newswire Clinical Trials on July 17, 2026 1:00 PM

Read Original